ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CTY / options
SPTX (48) HROW (53) JANX (37) MLTX (32) ⌘ Pro Terminal →

City Therapeutics Inc. (CTY) Options Positioning, Max Pain & Unusual Sweeps

$20.71 -6.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.43

City Therapeutics Inc. (CTY) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $1.04B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, City Therapeutics Inc. (NASDAQ: CTY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $20.71 (-6.46% 1D, market cap $1.04B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CTY ranks #263 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CTY compare to SPTX and HROW in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTY carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPTX (Seaport Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B) and HROW (Harrow Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B). Among the 5-stock peer group, CTY leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTY?
▼

For City Therapeutics Inc. (CTY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #263 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.43 (-1.35%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510050
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (6)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
$25 Bull$20 Base$16 Bear
📬 FREE CTY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY CTY SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.7% FCF Margin ($29.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
58
Grade C$21.46-3.2% Next Q
Q2 (-2Q)
55
Grade C$20.77+4.2% Next Q
Q3 (-1Q)
53
Grade C-$21.65-4.3% Next Q
Current
50
Grade D$20.71-1.4% Hist 90D α
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTY currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.73) and Max Pain ($21.75) forces dealer call-delta covering toward $25.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 50%NO 50%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CTY)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CTY.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTY)

  • ✓Walkthrough of CTY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CTY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.54%
2026-11-02O $21.08H $22.65L $19.19C $20.71VOL 224.4K
SMA50: $21.13
$24.21$22.85$21.49$20.13$18.77$20.712026-10-162026-10-202026-10-232026-10-282026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTY Butterfly Map → + Track CTY →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTY)

Health Care Rank #263 of 1016 ⚔️ SPTX vs CTY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTY vs. SPTX, HROW, JANX, MLTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, City Therapeutics Inc. (CTY) ranks #263 by composite RQD confidence (50/100, grade D) and #354 by equity capitalization ($1.04B). Within this direct 5-issuer industry benchmark cohort, CTY leads on earnings valuation at N/A trailing P/E, while HROW leads on capital efficiency and profitability with 42.9% ROIC and 75.1% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with CTY at 50/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CTY ACTIVE
City Therapeutics Inc.
D 50/100 — — — -6.46% $1.04B Benchmark Subject
SPTX
Seaport Therapeutics Inc.
D 48/100 — — — -7.11% $1.05B /sptx-vs-cty →
HROW
Harrow Inc.
D+ 53/100 — 75.1% 42.9% -5.83% $1.06B /hrow-vs-cty →
JANX
Janux Therapeutics Inc.
D- 37/100 — — -13.8% -2.02% $1.07B /janx-vs-cty →
MLTX
MoonLake Immunotherapeutics (Class A)
E 32/100 — — -35.0% -6.28% $1.00B /mltx-vs-cty →

2. CTY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

City Therapeutics Inc. (CTY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.04B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. CTY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, City Therapeutics Inc. (NASDAQ: CTY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $20.71 (-6.46% 1D, market cap $1.04B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CTY ranks #263 in composite RQD confidence.

How does CTY compare to SPTX and HROW in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTY carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPTX (Seaport Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B) and HROW (Harrow Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B). Among the 5-stock peer group, CTY leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTY?

For City Therapeutics Inc. (CTY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #263 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTY trading relative to its 50-day, 200-day, and 52-week technical levels?

CTY last traded at $20.71 (-6.46% on volume of 116,796 shares), positioning the stock -4.69% below its 50-day simple moving average ($21.73) and -1.38% below its 200-day simple moving average ($21.00). Across its 52-week range of $19.75 to $23.88, CTY sits at the 23.2% percentile with a 14-day RSI of 53.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.12 to $23.30).

CTY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CTY's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CTY.

Direct Sub-Reports: CTY RQD Cockpit CTY 12M Forecast CTY Earnings & Move CTY Dividends & DRIP CTY Insiders & 13F CTY Whale Options CTY Profit Sankey CTY News & Why
ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CTY — City Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

The RQD Score is 60 out of 100, a letter grade of C-, and the verdict label is "Roarable Hold — Cautious Neutral" (per the Roarable RQD rating). Across its five pillars:

  • Fundamental Cash Engine: 12 / 20. This pillar reflects ROIC of 0% and FCF yield of 0% (per the Roarable RQD rating and market data). A zero return on invested capital and zero free-cash-flow yield mean the source data shows no current cash-generation support for the valuation.
  • Whale 13F Flow: 11 / 20. Scored on institutional accumulation and options positioning. No holder-level detail is available in the source data to explain the score beyond the pillar value itself.
  • Insider Conviction: 9 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. This is the lowest pillar score, indicating weaker insider-side conviction signals per the rating.
  • Macro Regime Fit: 15 / 20. Reflects a Beta of 1.0 and sector sensitivity (per the Roarable RQD rating and market data). The stock tracks broad market volatility at the market-average level.
  • Forensic Balance Sheet: 13 / 20. Based on Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5 (per the Roarable RQD rating).

For a prospective investor evaluating the stock today, the upside drivers visible in the data are the balance-sheet pillar and the macro-regime pillar, both of which sit in the middle-to-upper range of their scales. The valuation tradeoff is that the cash-engine pillar is weak (ROIC and FCF yield both 0%), so any thesis must rest on factors other than current cash generation. The insider pillar being lowest suggests the rating does not currently find strong insider-conviction support. The overall grade of C- and "Cautious Neutral" verdict indicate the rating system does not currently rate the setup as favorable on a risk-adjusted basis. This is educational analysis, not personalized financial advice.

Recent Catalysts & News Wire Analysis

  • Upsized IPO pricing (CATALYST, GREEN): Bloomberg reports the stock jumped 24% after an upsized IPO (per the news wire).
  • IPO pricing at $18 per share (MARKET WIRE): Investing.com and Seeking Alpha report pricing at $18 per share, with Investing.com citing $200M raised (per the news wire).
  • Shelf registration (MARKET WIRE): Yahoo Finance reports a $239.1 million shelf registration filed after the IPO (per the news wire).
  • Offering size (MARKET WIRE): Quartz reports the company sought up to $185 million in a U.S. IPO (per the news wire).
  • Risk watch: The most recent price action shows a -6.46% change (per market data), and the stock trades near the lower end of its 52-week range of $19.75 - $23.88 (per market data).
  • Proprietary signals: None (per the Butterfly Supply-Chain Graph).

Open Questions

  • What are the reported revenue, operating income, net income, and cash-flow figures by period, given that the financials section is empty?
  • What is the company's clinical pipeline and regulatory status for its RNAi candidates, which the source data does not describe?
  • How does the $18 IPO price relate to the current $20.71 price and the 52-week range, and what lockup or share-supply dynamics apply?
  • Who are the institutional and insider holders, given that the holders section is empty?
  • What is the cash runway and how is the company financing operations given zero reported margins and FCF yield?

CTY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for City Therapeutics Inc. (CTY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CTY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTY Bull vs. Bear Conversation Board — What's Your Call at $20.71?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTY 🐻 50% BEARISH CONVICTION
1. Pick Your Side on CTY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $22.37 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CTY (C- • RQD 60/100) a Buy at $20.71?

Welcome to the CTY (City Therapeutics Inc.) Roar Pit. Current RQD Composite is 60/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $15.53 (-25.0%)
Spot @ $20.71

Pump the brakes on CTY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CTY, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless City Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $25.47 (+23.0%)
Spot @ $20.71

CTY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CTY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $20.71 (52-wk range $19.75 - $23.88), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%